Silent hypoxia in COVID-19: pathomechanism and possible management strategy
Autor: | Ahsab Rahman, Tahani Tabassum, Mohammad Jakir Hosen, Yusha Araf, Abdullah Al Nahid, Asad Ullah |
---|---|
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
2019-20 coronavirus outbreak medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Blood gas levels Low oxygen saturation Mini Review Article 03 medical and health sciences 0302 clinical medicine Pathomechanism Dyspnoea Genetics Humans Medicine Oximetry Hypoxia Intensive care medicine Molecular Biology business.industry Walking test Silent hypoxia COVID-19 General Medicine Hypoxia (medical) Management Management strategy 030104 developmental biology 030220 oncology & carcinogenesis Practice Guidelines as Topic Angiotensin-Converting Enzyme 2 Hypoxia-Inducible Factor 1 Blood Gas Analysis medicine.symptom business |
Zdroj: | Molecular Biology Reports |
ISSN: | 1573-4978 0301-4851 |
DOI: | 10.1007/s11033-021-06358-1 |
Popis: | The novel coronavirus disease 2019 (COVID-19) has become a severe health issue, especially to the patients who develop silent hypoxia condition after SARS-CoV-2 infection. Due to the lack of dyspnoea and extremely low oxygen saturation level, these patients are at exceptionally higher risk. Although the prevalence of silent hypoxia in COVID-19 patients has been evident in several cases, the underlying pathomechanism behind this condition is still unclear. Silent hypoxia in SARS-CoV-2 infected patients can be diagnosed with the help of a pulse oximeter, blood gas levels, and a 6-min walking test. While the clinicians and researchers figure out the exact reason for this phenomenon, the patients must be under strict day-to-day monitoring. In this article, we aim to provide comprehensive insights into the underlying symptoms, mechanism, and possible factors behind the occurrence of silent hypoxia among COVID-19 patients. |
Databáze: | OpenAIRE |
Externí odkaz: |